tetano
Editor, Senior Moderator
Sci Transl Med
. 2020 Oct 19;eabe0948.
doi: 10.1126/scitranslmed.abe0948. Online ahead of print.
Prospects for a safe COVID-19 vaccine
Barton F Haynes[SUP] 1 [/SUP], Lawrence Corey[SUP] 2 [/SUP], Prabhavathi Fernandes[SUP] 2 [/SUP], Peter B Gilbert[SUP] 2 [/SUP], Peter J Hotez[SUP] 2 [/SUP], Srinivas Rao[SUP] 2 [/SUP], Michael R Santos[SUP] 2 [/SUP], Hanneke Schuitemaker[SUP] 2 [/SUP], Michael Watson[SUP] 2 [/SUP], Ann Arvin[SUP] 2 [/SUP]
Affiliations
Abstract
Rapid development of an efficacious vaccine against the viral pathogen SARS-CoV-2, the cause of the coronavirus disease-2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and post-licensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, following vaccination.
. 2020 Oct 19;eabe0948.
doi: 10.1126/scitranslmed.abe0948. Online ahead of print.
Prospects for a safe COVID-19 vaccine
Barton F Haynes[SUP] 1 [/SUP], Lawrence Corey[SUP] 2 [/SUP], Prabhavathi Fernandes[SUP] 2 [/SUP], Peter B Gilbert[SUP] 2 [/SUP], Peter J Hotez[SUP] 2 [/SUP], Srinivas Rao[SUP] 2 [/SUP], Michael R Santos[SUP] 2 [/SUP], Hanneke Schuitemaker[SUP] 2 [/SUP], Michael Watson[SUP] 2 [/SUP], Ann Arvin[SUP] 2 [/SUP]
Affiliations
- PMID: 33077678
- DOI: 10.1126/scitranslmed.abe0948
Abstract
Rapid development of an efficacious vaccine against the viral pathogen SARS-CoV-2, the cause of the coronavirus disease-2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and post-licensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, following vaccination.